Document is current
Any future updates will be listed below
-
Authors
Fiascarelli, Alessio https://orcid.org/0000-0002-7453-4262
Merlino, Giuseppe
Capano, Stefania
Talucci, Simone
Bisignano, Diego
Bressan, Alessandro
Bellarosa, Daniela
Carrisi, Corrado
Paoli, Alessandro
Bigioni, Mario
Tunici, Patrizia
Irrissuto, Clelia
Salerno, Massimiliano
Arribas, Joaquin
de Stanchina, Elisa
Scaltriti, Maurizio
Binaschi, Monica
-
Funding
Funding for this research was provided by:
Regione Lazio
- License Information
-
More Information
Article History
Received: 10 August 2022
Accepted: 14 February 2023
First Online: 13 March 2023
Declarations
:
: Maurizio Scaltriti is an employee and stock holder for AstraZeneca. Joaquim Arribas has received research funds from Roche, Synthon, Menarini, and Molecular Partners, consultancy honoraria from Menarini and license fees on patents EP 16191933.7 and EP20382457.8, from Innocent and Mnemo, respectively. No potential conflicts of interest were disclosed by the other authors.
: Environmental conditions, as well as the procedures for housing and handling the animals, were in compliance with the UKCCCR guideline (4) and the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes (2010/63/EU; ref 5). The in vivo studies conducted at Memorial Sloan Kettering Cancer Center were cared for in accordance with guidelines approved by the Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Animal Care and Use Committee (IACUC) and Research Animal Resource Center (RARC).
